Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-5684 vs alternative abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer
jRCT2031240029Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- May 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of opevesostat in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Merck & Co. Primary endpoints: Overall Survival and Radiographic Progression-Free Survival. Started May 2024; status: recruiting.
02
Drugs
opevesostat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2031240029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240029.